Study shows potential for digital microscopy for real-time...
Strategies to procure high-quality core-needle biopsy (CNB) specimens are critical for making basic tissue diagnoses and for ancillary...
Phase I clinical trial shows WNT974 in combination with...
An MD Anderson Phase I clinical trial demonstrated that a combination therapy using WNT974, a drug that targets the WNT pathway in...
Combination therapy key in two studies of blood cancers...
Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic...
Triple combination therapy with nivolumab is feasible for AML, MDS...
The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute...
Study defines genetic pathway for hard-to-treat form of...
A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use...
New approach enhances PD-L1 detection to aid in...
Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer...
Novel oncogene hnRNPK identified for B-cell lymphomas
Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as...
Combination chemotherapy before blood stem cell transplant...
A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The...
Funding that makes a difference for cancer patients
Whether it is new clinical trials for pediatric cancers or programs designed to increase access to smoking cessation programs for...
Clinical trials lead to FDA approval of two drugs for acute...
Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved...